Idioma: Inglés
Publicado por Chapman and Hall/CRC Press, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Librería: Salish Sea Books, Bellingham, WA, Estados Unidos de America
EUR 53,04
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: Very Good. Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam padding; Medium Format (8.5" - 9.75" tall); Dark blue and aqua covers with title in white lettering; 2013, Chapman and Hall/CRC Press; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Librería: Salish Sea Books, Bellingham, WA, Estados Unidos de America
EUR 70,73
Cantidad disponible: 1 disponibles
Añadir al carritoHardcover. Condición: Very Good. 1439867941 Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam padding; Medium Format (8.5" - 9.75" tall); Aqua and blue covers with title in white lettering; 2013, Chapman and Hall/CRC; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Librería: Broad Street Books, Branchville, NJ, Estados Unidos de America
EUR 79,58
Cantidad disponible: 1 disponibles
Añadir al carritohardcover. Condición: New. Brand New Book.
Librería: Studibuch, Stuttgart, Alemania
EUR 25,84
Cantidad disponible: 1 disponibles
Añadir al carritohardcover. Condición: Sehr gut. 220 Seiten; 9781439867945.2 Gewicht in Gramm: 1.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 116,85
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 130,56
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 119,74
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 119,63
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: THE SAINT BOOKSTORE, Southport, Reino Unido
EUR 125,11
Cantidad disponible: 1 disponibles
Añadir al carritoHardback. Condición: New. New copy - Usually dispatched within 4 working days.
Idioma: Inglés
Publicado por Taylor & Francis Group, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 140,21
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New. pp. 220.
Idioma: Inglés
Publicado por Taylor & Francis Group, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 142,87
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New. pp. 220.
Librería: moluna, Greven, Alemania
EUR 118,51
Cantidad disponible: Más de 20 disponibles
Añadir al carritoGebunden. Condición: New.
Idioma: Inglés
Publicado por Taylor & Francis Inc Nov 2013, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 146,37
Cantidad disponible: 2 disponibles
Añadir al carritoBuch. Condición: Neu. Neuware - Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule's journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies.The book also focuses on a molecule's entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety. Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
Idioma: Inglés
Publicado por Taylor & Francis Group, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Librería: Majestic Books, Hounslow, Reino Unido
EUR 125,20
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New. pp. 220 A 7 fig, 4-page color insert will appear of Figs. 5.10-5.16. follows page 96 This item is printed on demand.